Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975250 | 0.91 | MAPT (0.53) | PYGMPYGL | |
| SCHEMBL975483 | 0.90 | PYGM (0.56) | PYGM | |
| SCHEMBL978414 | 0.86 | TDP1 (0.54) | PYGMPYGL | |
| SCHEMBL472749 | 0.84 | — | — | |
| SCHEMBL27943418 | 0.78 | MAPT (0.67) | PYGM | |
| SCHEMBL15464521 | 0.78 | CYP1A2 (0.50) | PYGMPYGL | |
| SCHEMBL12189439 | 0.78 | PYGM (0.66) | PYGMPYGL | |
| SCHEMBL5896940 | 0.77 | L3MBTL1 (0.74) | PYGMPYGL | |
| SCHEMBL975482 | 0.77 | PYGM (0.58) | PYGMPYGL | |
| SCHEMBL7129478 | 0.77 | PYGL (0.72) | PYGMPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| EP-2217588-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | PYGM 3083/4885PYGL 2595/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | PYGM 3083/4885PYGL 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.